Clinical Trial Update: Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum) [Phase 4]

View source ↗

Summary

Phase 4 safety assessment study for iron sucrose in CKD patients intolerant to other iron therapies has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Deficiency Anemia

Drugs mentioned

• VENOFER (Iron sucrose)

Snippet

Sponsor: American Regent, Inc. | Conditions: Iron Deficiency Anemia | Phase 4 | Status: WITHDRAWN